

Freedom of Information Request

Ref: 21-392

3 August 2021

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we hold some the information you are requesting

I am researching the incidence and treatment of oesophageal and gastric cancer. I would greatly appreciate if you could answer the following questions.

Q1. Does your trust treat the following conditions?

- **Advanced oesophageal cancer - Yes**
- **Advanced gastric cancer - Yes**
- **In case you do not treat either of the above conditions, which other trust do you refer these patients to?**

Not applicable

Q2. Please provide the total number of patients treated in the last 6 months for

- **Oesophageal cancer (any type)**
- **Oesophageal adenocarcinoma**
- **Oesophageal squamous cell carcinoma**
- **Unresectable oesophageal squamous cell carcinoma**
- **Gastric cancer (any type)**
- **HER2 negative or HER2 untested gastric cancer**

Description	Treatment Date	Number of patients treated
Gastric cancer	Jan	*
	Feb	*
	Mar	6
	Apr	*
	May	*
	Jun	6
	Jul	*

	Feb	22
Oesophageal cancer	Mar	23
	Apr	14
	May	26
	Jun	20
	Jul	9
Description	Treatment Date	Number of patients treated
	Feb	*
	Mar	*
M80703 - Squamous cell carcinoma	Apr	*
	May	*
	Jun	*
	Jul	*
	Jan	*
	Feb	13
M81403 Adenocarcinoma	Mar	23
	Apr	14
	May	22
	Jun	17
	Jul	6
M81443 Adenocarcinoma, intestinal type	Feb	*

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. (Section 40 is the exemption for personal information).

Q3. For oesophageal squamous cell carcinoma only, how many patients were treated in the past 6 months with:

- **Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) - ***
- **Any other systemic anti-cancer therapy - 7**
- **Palliative care only - We do not hold this information**

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of

information Act 2000 is engaged. (Section 40 is the exemption for personal information).

Q4. For gastric cancer only, how many patients were treated in the past 6 months with:

- **CapeOx (Capecitabine with Oxaliplatin) - ***
- **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) - 7**
- **Any other systemic anti-cancer therapy - ***
- **Palliative care only - We do not hold this information**

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. (Section 40 is the exemption for personal information).

Q5. Does your trust participate in any ongoing clinical trials for the treatment of oesophageal cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Q6. Does your trust participate in any ongoing clinical trials for the treatment of gastric cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Q5 & Q6

Please find below information about the relevant trials we have running here.

This is a combination of gastric and oesophageal.

A Phase 3, Global, Multi-Centre, Double-Blind, Randomised, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (commercial trial)

A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET) (non-commercial trial)

Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial (PLATFORM Trial) (non-commercial trial)

A randomised Phase II study of two preoperative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin) for resectable oesophageal cancer. (non-commercial trial)

Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge) for post chemo-

radiotherapy surveillance in patients with oesophageal cancer – a feasibility study (non-commercial trial)

A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585) (commercial trial)

Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (MAGIC regimen) vs. neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the oesophagus and oesophago-gastric junction. (non-commercial trial)

There is not information in the public domain about the number of participants at a site level before the study is closed. You can look at this link for information at a study level for the non-commercial trials https://public-odp.nihr.ac.uk/QvAJAXZfc/opendoc.htm?document=crncc_users%5Cfind%20a%20clinical%20research%20study.qvw&lang=en-US&host=QVS%40crn-prod-odp-pu&anonymous=true and select the “STUDY Search” tab.

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance
University Hospitals Bristol and Weston NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner’s Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust’s Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information

(such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

Freedom of Information Team
University Hospitals Bristol and Weston NHS Foundation Trust